Novel heterozygous variants in the EP300 gene cause Rubinstein-Taybi syndrome 2: Reports from two Chinese children
- PMID: 37162176
- PMCID: PMC10496081
- DOI: 10.1002/mgg3.2192
Novel heterozygous variants in the EP300 gene cause Rubinstein-Taybi syndrome 2: Reports from two Chinese children
Abstract
Background: Rubinstein-Taybi syndrome (RSTS) is a rare autosomal-dominant genetic disease caused by variants of CREBBP (RSTS1) or EP300 (RSTS2) gene. RSTS2 is much less common, with less than 200 reported cases worldwide to date. More reports are still needed to increase the understanding of its clinical manifestations and genetic characteristics.
Methods: The clinical data of two children with RSTS2 were analyzed retrospectively, and their clinical manifestations, auxiliary examinations, and mutational spectrum were summarized. Liquid chromatography-tandem mass spectrometer (LC-MS/MS) technology was used to detect the levels of steroid hormones if possible.
Results: After analyzing the clinical and genetic characteristics of two boys with RSTS2 (0.7 and 10.4 years old, respectively) admitted in our hospital, we identified two novel heterozygous variants in the EP300 exon 22 (c.3750C > A, p. Cys1250*, pathogenic; c.1889A > G, p. Tyr630Cys, likely pathogenic), which could account for their phenotype. In addition to common clinical manifestations such as special facial features, microcephaly, growth retardation, intellectual disability, speech delay, congenital heart defect, recurrent respiratory infections, and immunodeficiency, we found one of them had a rare feature of adrenal insufficiency, and LC-MS/MS detection showed an overall decrease in steroid hormones.
Conclusion: In our study, we identified two novel variants in the EP300 exon 22, and for the first time, we reported a case of RSTS2 associated with adrenal insufficiency, which will enrich the clinical and mutational spectrum of this syndrome.
Keywords: EP300; LC-MS/MS; Rubinstein-Taybi syndrome; adrenal insufficiency; genotype.
© 2023 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.
Conflict of interest statement
All authors declare that they have no conflict of interest.
Figures
References
-
- Bamforth, S. D. , Bragança, J. , Eloranta, J. J. , Murdoch, J. N. , Marques, F. I. , Kranc, K. R. , Farza, H. , Henderson, D. J. , Hurst, H. C. , & Bhattacharya, S. (2001). Cardiac malformations, adrenal agenesis, neural crest defects and exencephaly in mice lacking Cited2, a new Tfap2 co‐activator. Nature Genetics, 29(4), 469–474. 10.1038/ng768 - DOI - PubMed
-
- Chen, W. Y. , Juan, L. J. , & Chung, B. C. (2005). SF‐1 (nuclear receptor 5A1) activity is activated by cyclic AMP via p300‐mediated recruitment to active foci, acetylation, and increased DNA binding. Molecular and Cellular Biology, 25(23), 10442–10453. 10.1128/mcb.25.23.10442-10453.2005 - DOI - PMC - PubMed
-
- Kasper, L. H. , Fukuyama, T. , Lerach, S. , Chang, Y. , Xu, W. , Wu, S. , Boyd, K. L. , & Brindle, P. K. (2013). Genetic interaction between mutations in c‐Myb and the KIX domains of CBP and p300 affects multiple blood cell lineages and influences both gene activation and repression. PLoS ONE, 8(12), e82684. 10.1371/journal.pone.0082684 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
